Cipla unit's US facility receives 5 observations from American drug regulator; shares fall

Cipla shares remained under pressure on Thursday after the US drug regulator issued five observations about a New York-based facility of the company's wholly-owned subsidiary, InvaGen Pharmaceuticals. 

Cipla unit's US facility receives 5 observations from

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x